Necrosis inhibitors

A method of treating a necrosis-associated disease or condition, comprising administering an effective amount of a composition to a patient in need thereof, the composition comprising a compound, or a pharmaceutically acceptable salt, hydrate or stereoisomer of the compound or corresponding sulfonamide, and a pharmaceutically-acceptable excipient, in unit dosage, wherein the compound is an inhibitor of cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), of formula:

• wherein:
• R1 is (a) substituted or unsubstituted phenyl;
• (b) substituted or unsubstituted 2-, 3- or 4-pyridine;
• (c) substituted or unsubstituted naphthyl or 3-azanaphthyl;
• (d) substituted or unsubstituted 0-3 heteroatom cyclohexyl, cyclopentyl;
• or
• (e) substituted or unsubstituted 0-3 heteroatom cyclopentene or cyclopentadiene;
• R2 is substituted or unsubstituted aziridine, azetidine, pyrrolidine, piperidine, oxazridine, oxazetidine, oxazolidine, oxazinane, thiaziridine, thiazetidine, thiazolidine, thiazinane, diaziridine, diazetidine, diazolidine (pyrazolidine), diazinane;
• or
• R2 is substituted or unsubstituted pyrrole, dihydropyrrole, pyridine, dihydropyridine, tetrahydropyridine, azole, pyrimidine, oxazine, thiazine, triazine, ozadiazine, thiadiazine;
• and
• R3 is substituted or unsubstituted, 0-3 heteroatom C1-C9 alkyl, alkenyl, or alkynyl;
• or
• a corresponding sulfonamide of the amide compound, or
• a pharmaceutically acceptable salt, hydrate or stereoisomer the compound or corresponding sulfonamide.